Artemis Medicare Services Ltd (AMSL) was incorporated on May 18, 2004, by the promoters of the Apollo Tyres Group, establishing itself as a prominent healthcare provider in India. The company commenced commercial operations by setting up Artemis Hospital (formerly Artemis Health Institute) at Gurugram on July 16, 2007, marking the beginning of its journey in the healthcare sector.
Artemis Hospital, the flagship unit of Artemis Medicare Services Limited, is spread across 9 acres and operates as a 395-bed state-of-the-art multi-specialty hospital located in Gurugram, India. The hospital has been designed as one of the most advanced healthcare facilities in the country, providing comprehensive medical and surgical interventions along with a full spectrum of inpatient and outpatient services.
The specialty areas for AMSL include Orthopaedics, Oncology, Cardiovascular, Neurosciences and Bariatric & Minimally Invasive Surgery. The company has established itself as a leader in advanced medical technology, with successful performance of over 1000 Cyberknife surgeries with high success rates, along with successful transplants, cardiac care and oncology treatments.
AMSL has been awarded with the NABH and JCI accreditation, demonstrating its commitment to maintaining international quality standards in healthcare delivery. The company has also diversified its healthcare presence through multiple models including Artemis Daffodil, Artemis Lite, Artemis Cardiac Care and Artemis Solace.
As of March 2025, Artemis Medicare Services holds a market capitalization of ₹3,527 crores, reflecting its significant presence in the healthcare sector. The company has demonstrated strong financial performance with revenue of ₹913 crores and profit of ₹83.5 crores in the latest financial year.
The company's geographical revenue break-up for 9MFY24 shows domestic operations contributing approximately 76% while international operations account for 24%, demonstrating the company's growing international footprint in healthcare services.
- Market Capitalization: ₹3,527 Crore (as of March 2025)
- Revenue (Latest Financial Year): ₹913 Crore
- Profit (Latest Financial Year): ₹83.5 Crore
- Revenue Growth: Annual revenue growth of 19% with operating revenue of ₹922.26 crores on a trailing 12-month basis.
- Profitability: Pre-tax margin of 8% and ROE of 12%.
- Q3 FY25 Performance: Total income of ₹241.19 crores, representing a 9.3% year-over-year increase from ₹220.57 crores in Q3FY24.
- Profit Growth (Q3 FY25): Profit after tax stood at ₹20.60 crores, showing a significant 78.4% increase from ₹11.55 crores in Q3FY24.
Promoter holding stands at 67.2%, indicating strong promoter commitment to the company's growth. The company serves as the holding company of Artemis Cardiac Care Private Limited and is a subsidiary of Constructive Finance Private Limited. The management team is led by Dr. Devlina Chakravarty as Managing Director and Onkar S Kanwar as Chairman.
In a significant strategic move, the company successfully raised ₹3,300 million from International Finance Corporation (IFC), a member of the World Bank Group, to accelerate growth plans. This funding will enable the company to expand its presence in the super-specialty segment through the addition of larger-sized hospitals.
However, as part of operational restructuring, Artemis Medicare Services announced the closure of its cardiac centre in Chennai, effective January 23, 2025, as the unit contributed only 0.25% to the company's total turnover.
The stock trades on both NSE and BSE under the symbol ARTEMISMED. Key investment metrics include:
- Market Cap: ₹3,527 crores (as of latest available data)
- P/E Ratio: 43.56 (as of March 2025)
- Book Value: ₹61.2 per share
- Dividend Yield: 0.18%
- 52-Week Range: ₹141.3 - ₹350
The stock is currently trading at 4.15 times its book value, while the company has maintained a return on equity of 11.7% over the last 3 years.
Artemis Medicare Services is positioned to capitalize on India's growing healthcare demand with its established infrastructure, quality accreditations, and recent funding injection. The company's focus on super-specialty care, advanced medical technology, and international quality standards provides a solid foundation for future growth in the expanding Indian healthcare market.
